Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis
International Immunopharmacology · 2024-06 · 135 · 112269
DOI: 10.1016/j.intimp.2024.112269 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024-06. Verfasst von Purnima Tiwari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Toxicology and Experimental Medicine, CSIR- Central Drug Research Institute (CSIR-CDRI), Lucknow-226031, India. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 135 Literaturangaben.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) presents a challenging progression characterized by lung tissue scarring and abnormal extracellular matrix deposition. This review examines the influence of immune responses, emphasizing their complex role in initiating and perpetuating fibrosis. It highlights how metabolic pathways modulate immune cell function during IPF. Immune cell modulation holds promise in managing pulmonary fibrosis (PF). Inhibiting neutrophil recruitment and monitoring mast cell levels offer insights into PF progression. Low-dose IL-2 therapy and regulation of fibroblast recruitment present potential therapeutic avenues, while the role of innate lymphoid cells (ILC2s) in allergic lung inflammation sheds light on disease mechanisms. The review focuses on metabolic reprogramming's role in shaping immune cell function during IPF progression. While some immune cells use glycolysis for pro-inflammatory responses, others favor fatty acid oxidation for regulatory functions. Targeting specialized pro-resolving lipid mediators (SPMs) presents significant potential for managing fibrotic disorders. Additionally, it highlights the pivotal role of amino acid metabolism in synthesizing serine and glycine as crucial regulators of collagen production and exploring the interconnectedness of lipid metabolism, mitochondrial dysfunction, and adipokines in driving fibrotic processes. Moreover, the review discusses the impact of metabolic disorders such as obesity and diabetes on lung fibrosis. Advocating for a holistic approach, it emphasizes the importance of considering this interplay between immune cell function and metabolic pathways in developing effective and personalized treatments for IPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Toxicology and Experimental Medicine, CSIR- Central Drug Research Institute (CSIR-CDRI), Lucknow-226031, India.
- Division of Toxicology and Experimental Medicine, CSIR- Central Drug Research Institute (CSIR-CDRI), Lucknow-226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.
- Division of Toxicology and Experimental Medicine, CSIR- Central Drug Research Institute (CSIR-CDRI), Lucknow-226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India. Electronic addr…
Zitieren
APA
Tiwari, P., Verma, S., Washimkar, K. R., & Nilakanth Mugale, M. (2024). Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis. International Immunopharmacology, 135, 112269. https://doi.org/10.1016/j.intimp.2024.112269
Vancouver
Tiwari P, Verma S, Washimkar KR, Nilakanth Mugale M. Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis. International Immunopharmacology. 2024;135:112269. doi:10.1016/j.intimp.2024.112269
BibTeX
@article{Tiwari2024,
author = {Tiwari, Purnima and Verma, Shobhit and Washimkar, Kaveri R and Nilakanth Mugale, Madhav},
title = {Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis},
journal = {International Immunopharmacology},
year = {2024},
volume = {135},
pages = {112269},
doi = {10.1016/j.intimp.2024.112269}
}
EUVIMED